Cancer Drugs
Tecentriq
Also known as: Atezolizumab, Anti-PD-L1
Definition
Atezolizumab, a PD-L1 inhibitor checkpoint immunotherapy drug used to treat various cancers including lung, breast, and urothelial cancers.
Detailed Explanation
Tecentriq blocks PD-L1 protein on tumor cells and immune cells, preventing it from binding to PD-1 on T-cells. This allows the immune system to recognize and attack cancer cells. Unlike PD-1 inhibitors (Keytruda, OPDIVO), Tecentriq targets PD-L1 specifically.